English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

The Human Cdc37·Hsp90 Complex Studied by Heteronuclear NMR Spectroscopy

MPS-Authors
/persons/resource/persons137768

Lancaster,  C. Roy D.
Department of Molecular Membrane Biology, Max Planck Institute of Biophysics, Max Planck Society;
Department of Structural Biology, Saarland University, Faculty of Medicine, Building 60, Homburg D-66421, Germany ;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Sreeramulu, S., Jonker, H. R. A., Langer, T., Richter, C., Lancaster, C. R. D., & Schwalbe, H. (2009). The Human Cdc37·Hsp90 Complex Studied by Heteronuclear NMR Spectroscopy. The Journal of Biological Chemistry, 284(6), 3885-3896. doi:10.1074/jbc.M806715200.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0024-D779-8
Abstract
The cell division cycle protein 37 (Cdc37) and the 90-kDa heat shock protein (Hsp90) are molecular chaperones, which are crucial elements in the protein signaling pathway. The largest class of client proteins for Cdc37 and Hsp90 are protein kinases. The catalytic domains of these kinases are stabilized by Cdc37, and their proper folding and functioning is dependent on Hsp90. Here, we present the x-ray crystal structure of the 16-kDa middle domain of human Cdc37 at 1.88A˚ resolution and the structure of this domain in complex with the 23-kDa N-terminal domain of human Hsp90 based on heteronuclear solution state NMR data and docking. Our results demonstrate that the middle domain of Cdc37 exists as a monomer. NMR and mutagenesis experiments reveal Leu-205 in Cdc37 as a key residue enabling complex formation. These findings can be very useful in the development of small molecule inhibitors against cancer